Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early‐Stage Malignant Melanoma
ABSTRACT Background Melanoma is the most aggressive skin cancer with ability to recur also after early‐stage tumor surgery. The aim was to identify early‐stage melanoma patients at high risk of recurrence using liquid biopsy, estimating of mutated BRAF ctDNA and the level of tumor marker S100B in pl...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-10-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.70313 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849328930749677568 |
|---|---|
| author | Jiri Polivka Mohamed A. Gouda Mahyar Sharif Martin Pesta Helen Huang Inka Treskova Vlastimil Woznica Jindra Windrichova Katerina Houfkova Radek Kucera Tomas Fikrle Jan Ricar Kristyna Pivovarcikova Ondrej Topolcan Filip Janku |
| author_facet | Jiri Polivka Mohamed A. Gouda Mahyar Sharif Martin Pesta Helen Huang Inka Treskova Vlastimil Woznica Jindra Windrichova Katerina Houfkova Radek Kucera Tomas Fikrle Jan Ricar Kristyna Pivovarcikova Ondrej Topolcan Filip Janku |
| author_sort | Jiri Polivka |
| collection | DOAJ |
| description | ABSTRACT Background Melanoma is the most aggressive skin cancer with ability to recur also after early‐stage tumor surgery. The aim was to identify early‐stage melanoma patients at high risk of recurrence using liquid biopsy, estimating of mutated BRAF ctDNA and the level of tumor marker S100B in plasma. Methods Eighty patients were enrolled in the study. BRAF V600E mutation was determined in FFPE tissue and plasma samples using ultrasensitive ddPCR with pre‐amplification. The level of S100B was determined in plasma by immunoassay chemiluminescent method. Results The best prediction of melanoma recurrence after surgery was observed in patients with combined high level of S100B (S100Bhigh) and ctDNA BRAFV600E (BRAFmut) in preoperative (57.1% vs. 12.5%, p = 0.025) as well as postoperative blood samples (83.3% vs. 14.3%, resp., p = 0.001) in comparison with low S100B and BRAF wild‐type. Similarly, patients with preoperative and postoperative S100Bhigh and BRAFmut experienced worse prognosis (DFI p = 0.05, OS p = 0.131 and DFI p = 0.001, OS = 0.001, resp.). Conclusion We observed the benefit of the estimation of combination of S100B and ctDNA BRAFmut in peripheral blood for identification of patients at high risk of recurrence and unfavorable prognosis. Significance There is still no general consensus on molecular markers for deciding the appropriateness of adjuvant treatment of early‐stage melanoma. We have shown for the first time that the combined determination of the ctDNA BRAFmut oncogene (liquid biopsy) and the high level of tumor marker S100B in pre‐ and postoperative plasma samples can identify patients with the worst prognosis and the highest risk of tumor recurrence. Therefore, modern adjuvant therapy would be appropriate for these patients with resectable melanoma, regardless of disease stage. |
| format | Article |
| id | doaj-art-813949faa5b140ff89864ce7b2e7fc3e |
| institution | Kabale University |
| issn | 2045-7634 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cancer Medicine |
| spelling | doaj-art-813949faa5b140ff89864ce7b2e7fc3e2025-08-20T03:47:24ZengWileyCancer Medicine2045-76342024-10-011319n/an/a10.1002/cam4.70313Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early‐Stage Malignant MelanomaJiri Polivka0Mohamed A. Gouda1Mahyar Sharif2Martin Pesta3Helen Huang4Inka Treskova5Vlastimil Woznica6Jindra Windrichova7Katerina Houfkova8Radek Kucera9Tomas Fikrle10Jan Ricar11Kristyna Pivovarcikova12Ondrej Topolcan13Filip Janku14Department of Histology and Embryology, Faculty of Medicine in Pilsen Charles University Pilsen Czech RepublicDepartment of Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center Houston Texas USADepartment of Histology and Embryology, Faculty of Medicine in Pilsen Charles University Pilsen Czech RepublicDepartment of Biology, Faculty of Medicine in Pilsen Charles University Pilsen Czech RepublicDepartment of Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center Houston Texas USADepartment of Plastic Surgery University Hospital Pilsen Pilsen Czech RepublicDepartment of Plastic Surgery University Hospital Pilsen Pilsen Czech RepublicDepartment of Immunochemical Diagnostics University Hospital Pilsen Pilsen Czech RepublicDepartment of Biology, Faculty of Medicine in Pilsen Charles University Pilsen Czech RepublicDepartment of Immunochemical Diagnostics University Hospital Pilsen Pilsen Czech RepublicDepartment of Dermatovenerology University Hospital Pilsen Pilsen Czech RepublicDepartment of Dermatovenerology University Hospital Pilsen Pilsen Czech RepublicDepartment of Pathology University Hospital Pilsen Pilsen Czech RepublicDepartment of Immunochemical Diagnostics University Hospital Pilsen Pilsen Czech RepublicDepartment of Investigational Cancer Therapeutics The University of Texas MD Anderson Cancer Center Houston Texas USAABSTRACT Background Melanoma is the most aggressive skin cancer with ability to recur also after early‐stage tumor surgery. The aim was to identify early‐stage melanoma patients at high risk of recurrence using liquid biopsy, estimating of mutated BRAF ctDNA and the level of tumor marker S100B in plasma. Methods Eighty patients were enrolled in the study. BRAF V600E mutation was determined in FFPE tissue and plasma samples using ultrasensitive ddPCR with pre‐amplification. The level of S100B was determined in plasma by immunoassay chemiluminescent method. Results The best prediction of melanoma recurrence after surgery was observed in patients with combined high level of S100B (S100Bhigh) and ctDNA BRAFV600E (BRAFmut) in preoperative (57.1% vs. 12.5%, p = 0.025) as well as postoperative blood samples (83.3% vs. 14.3%, resp., p = 0.001) in comparison with low S100B and BRAF wild‐type. Similarly, patients with preoperative and postoperative S100Bhigh and BRAFmut experienced worse prognosis (DFI p = 0.05, OS p = 0.131 and DFI p = 0.001, OS = 0.001, resp.). Conclusion We observed the benefit of the estimation of combination of S100B and ctDNA BRAFmut in peripheral blood for identification of patients at high risk of recurrence and unfavorable prognosis. Significance There is still no general consensus on molecular markers for deciding the appropriateness of adjuvant treatment of early‐stage melanoma. We have shown for the first time that the combined determination of the ctDNA BRAFmut oncogene (liquid biopsy) and the high level of tumor marker S100B in pre‐ and postoperative plasma samples can identify patients with the worst prognosis and the highest risk of tumor recurrence. Therefore, modern adjuvant therapy would be appropriate for these patients with resectable melanoma, regardless of disease stage.https://doi.org/10.1002/cam4.70313BRAF V600EctDNAddPCRmelanomaS100B |
| spellingShingle | Jiri Polivka Mohamed A. Gouda Mahyar Sharif Martin Pesta Helen Huang Inka Treskova Vlastimil Woznica Jindra Windrichova Katerina Houfkova Radek Kucera Tomas Fikrle Jan Ricar Kristyna Pivovarcikova Ondrej Topolcan Filip Janku Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early‐Stage Malignant Melanoma Cancer Medicine BRAF V600E ctDNA ddPCR melanoma S100B |
| title | Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early‐Stage Malignant Melanoma |
| title_full | Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early‐Stage Malignant Melanoma |
| title_fullStr | Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early‐Stage Malignant Melanoma |
| title_full_unstemmed | Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early‐Stage Malignant Melanoma |
| title_short | Predictive Significance of Combined Plasmatic Detection of BRAF Mutations and S100B Tumor Marker in Early‐Stage Malignant Melanoma |
| title_sort | predictive significance of combined plasmatic detection of braf mutations and s100b tumor marker in early stage malignant melanoma |
| topic | BRAF V600E ctDNA ddPCR melanoma S100B |
| url | https://doi.org/10.1002/cam4.70313 |
| work_keys_str_mv | AT jiripolivka predictivesignificanceofcombinedplasmaticdetectionofbrafmutationsands100btumormarkerinearlystagemalignantmelanoma AT mohamedagouda predictivesignificanceofcombinedplasmaticdetectionofbrafmutationsands100btumormarkerinearlystagemalignantmelanoma AT mahyarsharif predictivesignificanceofcombinedplasmaticdetectionofbrafmutationsands100btumormarkerinearlystagemalignantmelanoma AT martinpesta predictivesignificanceofcombinedplasmaticdetectionofbrafmutationsands100btumormarkerinearlystagemalignantmelanoma AT helenhuang predictivesignificanceofcombinedplasmaticdetectionofbrafmutationsands100btumormarkerinearlystagemalignantmelanoma AT inkatreskova predictivesignificanceofcombinedplasmaticdetectionofbrafmutationsands100btumormarkerinearlystagemalignantmelanoma AT vlastimilwoznica predictivesignificanceofcombinedplasmaticdetectionofbrafmutationsands100btumormarkerinearlystagemalignantmelanoma AT jindrawindrichova predictivesignificanceofcombinedplasmaticdetectionofbrafmutationsands100btumormarkerinearlystagemalignantmelanoma AT katerinahoufkova predictivesignificanceofcombinedplasmaticdetectionofbrafmutationsands100btumormarkerinearlystagemalignantmelanoma AT radekkucera predictivesignificanceofcombinedplasmaticdetectionofbrafmutationsands100btumormarkerinearlystagemalignantmelanoma AT tomasfikrle predictivesignificanceofcombinedplasmaticdetectionofbrafmutationsands100btumormarkerinearlystagemalignantmelanoma AT janricar predictivesignificanceofcombinedplasmaticdetectionofbrafmutationsands100btumormarkerinearlystagemalignantmelanoma AT kristynapivovarcikova predictivesignificanceofcombinedplasmaticdetectionofbrafmutationsands100btumormarkerinearlystagemalignantmelanoma AT ondrejtopolcan predictivesignificanceofcombinedplasmaticdetectionofbrafmutationsands100btumormarkerinearlystagemalignantmelanoma AT filipjanku predictivesignificanceofcombinedplasmaticdetectionofbrafmutationsands100btumormarkerinearlystagemalignantmelanoma |